Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?

Zacks07-29

We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2455660502?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-07-29 21:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2455660502","market":"us","top_or_hot":-1,"title":"Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?","media":"Zacks","content":"<div>\n<p>We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-afmd-report-q2-earnings-134800451.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffimed (AFMD) to Report Q2 Earnings: What's in the Cards?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-29 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/affimed-afmd-report-q2-earnings-134800451.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-afmd-report-q2-earnings-134800451.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AFMD","symbol_name":"Affimed NV","start_time":0,"source_url":"https://finance.yahoo.com/news/affimed-afmd-report-q2-earnings-134800451.html","article_id":"2455660502","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455660502","pubTimestamp":1722260880,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig  and AFM28, being studied for different cancer indications, when it reports second-quarter 2024 earnings.Let’s see how things have shaped up for the quarter to be reported.Affimed’s revenues are related to a platform license provided to Genentech, a subsidiary of Roche RHHBY. Revenues in the last reported declined year over year, a trend most likely to have continued in the to-be-reported quarter.AFM28 is being evaluated as a monotherapy in a phase I dose-escalation study for the treatment of refractory acute myeloid leukemia.The LuminICE-203 study is evaluating acimtamig in combination with AlloNK cells in patients with refractory Hodgkin's Lymphoma.The phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s oncology drug, Tecentriq , for the treatment of refractory patients with non-small cell lung cancer .Earnings ESP: Affimed has an Earnings ESP of 0","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AFMD":"Affimed NV"},"translate_title":"Affimed(AFMD)将报告第二季度收益：前景如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFMD":1},"content_text":"We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports second-quarter 2024 earnings.\nLet’s see how things have shaped up for the quarter to be reported.\nFactors to Note\nAffimed’s revenues are related to a platform license provided to Genentech, a subsidiary of Roche RHHBY. Revenues in the last reported declined year over year, a trend most likely to have continued in the to-be-reported quarter.\nAFMD’s clinical-stage pipeline comprises three investigational candidates, AFM24, acimtamig (AFM13) and AFM28, which are currently being developed either as a monotherapy or in combination therapies with other agents for several oncology indications.\nAFM28 is being evaluated as a monotherapy in a phase I dose-escalation study for the treatment of refractory acute myeloid leukemia.\nThe LuminICE-203 study is evaluating acimtamig in combination with AlloNK cells in patients with refractory Hodgkin's Lymphoma.\nThe phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s oncology drug, Tecentriq (atezolizumab), for the treatment of refractory patients with non-small cell lung cancer (NSCLC).\nRoche’s Tecentriq is currently approved in the United States, EU and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer.\nInvestors will be keen to get more updates on the studies related to the pipeline candidates on the upcoming second-quarter earnings call.\nYear to date, shares of Affimed have plunged 18.1% against the industry’s 0.5% increase.\nImage Source: Zacks Investment Research\nResearch and development expenses declined in the last reported quarter owing to lower costs associated with the development of the AFM13 and AFM24. Also, general and administrative expenses decreased in the last reported quarter due to a decline in headcount and other expenses. It remains to be seen whether the same trend continued or reversed in the to-be-reported quarter.\nThe company’s cash, cash equivalents and investments were €48.5 million as of Mar 31, 2024.\nEarnings Surprise History\nAffimed has a mixed earnings surprise history. The company’s earnings beat estimates in two of the trailing three quarters and met the same on the remaining occasion. AFMD delivered an average surprise of 13.09%. In the last reported quarter, Affimed’s earnings beat estimates by 20.23%.\nEarnings Whispers\nOur proven model does not conclusively predict an earnings beat for Affimed this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.\nEarnings ESP: Affimed has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at a loss of $1.00 per share.\nZacks Rank: Affimed currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.\n\nAffimed N.V. Price and EPS Surprise\n  \nAffimed N.V. price-eps-surprise | Affimed N.V. Quote\n\nStocks to Consider\nHere are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.\nKrystal Biotech, Inc. KRYS has an Earnings ESP of +34.00% and a Zacks Rank #2.\nShares of Krystal Biotech have surged 72.3% in the year-to-date period. Earnings of Krystal Biotech beat estimates in two of the last four quarters and missed on the remaining two occasions. KRYS delivered an average negative earnings surprise of 21.46% in the last four quarters. KRYS is set to report second-quarter earnings on Aug 5.\nAmgen Inc. AMGN has an Earnings ESP of +0.48% and a Zacks Rank #3.\nShares of Amgen have risen 16.3% year to date. Amgen beat earnings estimates in each of the trailing four quarters, with the average earnings surprise being 6.42%. AMGN is set to report second-quarter earnings on Aug 6.\nStay on top of upcoming earnings announcements with the Zacks Earnings Calendar.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nAffimed N.V. (AFMD) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455660502"}